Skip to main content
receiving transit and import

Warm Arrival: Reading the Transit Record Before You Write Off the Vial

A liquefied gel pack is a shipping observation, not a stability finding — the finding comes from reconstructing how hot the parcel got, for how long, and comparing that against the storage condition on the label.

Greek Peptides Technical Desk13 min read

A parcel that arrives at ambient temperature, with a liquefied gel pack or none at all, is not evidence that the contents are degraded. It is evidence of one thing: the shipment was not held refrigerated for the whole journey. Whether that matters depends on the labelled storage condition, on how hot the parcel actually got, and on how long it stayed there — and none of those are answered by how the box felt in your hand. The decision on receipt is a documentation exercise, not a sensory one: reconstruct the transit record, compare estimated exposure against the labelled condition, and write down what you concluded and why.

What follows treats a delivered parcel as evidence, for a laboratory receiving research-use-only material in the United States or Canada. These compounds are supplied for research use only, are not medicinal products, and nothing here is guidance about anything other than handling and documenting laboratory material.

What the cold chain protects, and whether powder is in it

The storage condition on the label is the specification; everything else is inference. USP General Chapter <659> supplies the vocabulary the rest of the supply chain is written in: cold is 2° to 8°, and controlled room temperature is a mean kinetic temperature not exceeding 25°, with excursions between 15° and 30° permitted as experienced in pharmacies, hospitals and warehouses and during shipping [1]. Buried in that definition is the clause almost nobody reads: transient spikes up to 40° are permitted provided they do not exceed 24 hours, and higher spikes only if the manufacturer instructs [1].

That clause reframes a lot of panic. A parcel that sat in a warm van for an afternoon and arrived at 32° has not, on that basis alone, left the labelled condition of an article specified at controlled room temperature. Excursion tolerance is not a concession granted after the fact — it is written into the definition, because the people who wrote it knew what trailers and loading docks are like.

Whether a particular lyophilised compound is specified at 2° to 8°, at −20°, or at ambient rests on the supplier's stability data, which is exactly the thing worth asking about. USP <1079> states the governing principle: products are stored and transported according to predetermined conditions supported by stability data, and brief excursions outside the labelled condition may be acceptable provided stability data and a scientific or technical justification exist [2]. Acceptability is decided by data, not by the appearance of the package.

Abstract diagram of a temperature trace rising and falling across a timeline, with the area beneath the curve shaded to represent accumulated thermal exposure rather than a single peak.

Heat exposure is cumulative, not a threshold

"It got warm, so it is ruined" treats temperature as a switch. Degradation chemistry is a rate — or rather a set of pathways, each with its own rate. For reactions following an Arrhenius relationship the rate constant rises steeply and non-linearly with temperature, so an hour at 35° and three days at 25° are different quantities of the same currency, not a fail and a pass. The question is not whether it got warm, but how much of the material's thermal budget the journey spent.

Pharmacopoeial practice formalises this as mean kinetic temperature: one derived temperature that, maintained over a period, imposes the same thermal challenge as the actual varying profile. ICH Q1A(R2) defines the term and points at the 1971 Haynes formula for computing it [3][4]. USP <1079.2> applies it to excursions and is unusually candid about the limits — it expresses cumulative thermal stress and can be considered for excursions in transit, but may not be used to normalise uncontrolled storage, nor to justify a system with repeated excursions, which is by definition not in control and needs correcting [5]. The calculation window is fixed too: data going back 30 days from and including the high excursion temperature [5].

The clearest working illustration is the vaccine vial monitor — a chemical time-temperature indicator whose reaction rate is matched to the stability profile of the product it is attached to, darkening progressively and reaching an endpoint when accumulated exposure passes a preset limit [6]. WHO's performance specification defines its categories by exactly the trade this article is about [6].

Monitor categoryDays to endpoint at +37°Days to endpoint at +25°Time to endpoint at +5°
VVM30 (high stability)30 days193 daysNot less than 4 years
VVM14 (medium stability)14 days90 daysNot less than 3 years
VVM7 (moderate stability)7 days45 daysNot less than 2 years
VVM2 (least stable)2 daysNot specified225 days

Read the table for its shape, not as a rule for peptides. In the most heat-tolerant category, thirty days at 37° corresponds to 193 days at 25° and to years in a refrigerator [6]. Same chemistry, three wildly different budgets — and the ratio is the point. Against a budget shaped like that, a day in a hot van is a small deduction and a week in a sun-facing mailbox is a large one. Vaccines are not research peptides, so what transfers is the arithmetic, not the numbers.

What a gel pack does, and what it does not

A gel pack is a finite quantity of latent heat capacity. Once it has completed its phase change and equilibrated, it is a bag of room-temperature water and it stops doing anything. Arriving liquefied is the normal end state of a pack that worked, not proof of failure, which is why its condition on arrival carries almost no information by itself.

What would carry information is a qualified shipping system: an insulated container with a defined coolant configuration, tested against a defined ambient profile for a defined duration, with performance documented. That is the subject of PDA Technical Report No. 39 [7], and of WHO's model guidance for time- and temperature-sensitive products, which states the same expectation in a freely published form [8]. A gel pack in a padded mailer is not a qualified system, and no quantity of gel packs makes it one. "We shipped it cold" and "we shipped it in a qualified system with a documented duration claim" are different assertions, and only the second produces evidence.

The transit record: what evidence you actually have

Most parcels carry more temperature information than people assume, and most of it is free — but it perishes. Consumer tracking detail commonly ages out of public view within weeks, so a screenshot taken on the day of receipt is worth far more later than a recollection of it.

  • The carrier scan timeline. Each scan is a timestamped location, but the gaps between them are the informative part: a parcel showing nothing for three days between two facilities is reporting a three-day dwell you cannot see.
  • Ambient conditions at each location and time. Public weather archives give daily maxima for the city holding each scan — an upper bound on what a parcel could have seen, and defensible evidence provided you record it as an estimate rather than a measurement.
  • Customs and inspection holds, routinely the longest single dwell in an international transit and the least likely to occur in a controlled space; take the hold and release timestamps from the brokerage record [14].
  • Delivery and post-delivery time. Six hours on a sunny porch or in a metal mailbox can exceed everything the parcel saw in the carrier network, and that exposure belongs in the record.
  • Any data logger in the box — the only direct measurement. Record make, serial, calibration status and sampling interval: an uncalibrated device logging hourly and a calibrated one logging every minute are not equivalent evidence [8].
  • Packaging condition, photographed before anything is unpacked: outer damage, whether insulation was present, whether vials moved freely, whether closures and tamper-evident features are intact.
  • The stated storage condition and any documented excursion allowance, taken from the certificate of analysis rather than a support-chat message [2].

Why lyophilised powder tolerates more than solution does

A freeze-dried solid is a fundamentally different chemical environment from a solution. Water is both reactant and plasticiser; removing most of it removes the medium for hydrolysis and immobilises the molecule in an amorphous glass. The solid-state literature catalogues what still happens there — deamidation, peptide bond cleavage, oxidation, the Maillard reaction, β-elimination, and dimerisation or aggregation — and names the controlling variables as temperature, moisture content, excipients and physical state, amorphous or crystalline [9]. Lyophilisation slows these reactions by orders of magnitude; it does not abolish them.

The mobility framing sharpens it. In an amorphous solid, chemical reactivity broadly tracks molecular mobility, governed by the glass transition temperature of that formulation rather than of the compound in the abstract; a review across small molecules, peptides and proteins finds the correlation real but far from universal, with reactions proceeding well below the glass transition [10]. Two consequences follow. Residual moisture matters as much as temperature, because absorbed water lowers the cake's glass transition and mobilises what drying immobilised. And the temperature that matters belongs to the formulation in front of you — peptide, excipients, moisture — not to the word "peptide" [11].

The contrast with solution is stark. Working with model peptides in buffer at pH 7.4 and 37°, investigators measured first-order deamidation half-times across 306 asparaginyl sequences spread from roughly one day to 455 days, with the neighbouring residues rather than the compound class setting the rate [12]. That is in vitro solution chemistry on synthetic model peptides — not an animal study, not a human trial, not a measurement on a lyophilised lot in a mailer — and it should not be read across. What it establishes is that "peptides degrade when warm" is not one fact but hundreds of different rates.

The gap deserves naming plainly. There is no published excursion database covering the research peptides in circulation: no per-compound stability profile, no qualified shipper data, frequently no stability programme behind the storage sentence on the label. Anyone quoting a confident hour-count of heat tolerance is extrapolating. It is worth seeing what an evidenced allowance costs: WHO's controlled temperature chain permits time outside the 2° to 8° chain only where a manufacturer has generated the stability data and a regulator has approved a specific label claim, with testing at both 37° and 40° [13]. Absent evidence on that scale, a receiving decision is a documented risk judgement — and should be recorded as one.

Making a receiving decision you can defend

The goal is not certainty. It is a decision that someone reading your records in six months can follow and agree was reasonable on the information available. Quarantine first, decide second, and write down the reasoning either way.

  1. Photograph the parcel sealed, then the packaging as it opens, then the vials in position. Timestamps come free and cannot be reconstructed later.
  2. Quarantine the lot physically and in the record — a labelled hold with a reason, not an intention.
  3. Move the material to its labelled storage condition immediately. Letting an excursion continue while you investigate it is the one genuinely avoidable error here.
  4. Reconstruct the timeline from carrier scans and archived weather, and express estimated exposure as a range with its basis stated, not a figure carrying false precision.
  5. Compare that estimate against the labelled condition and the excursions it already permits, quoting the definition you relied on rather than paraphrasing it [1].
  6. Calculate mean kinetic temperature only from a real measured series — never from guesses, and never to wave through a lane that excurses repeatedly [5].
  7. Ask the supplier in writing for the stability basis of their storage statement, and record the answer, including when the answer is that none exists [2].
  8. Decide in writing: release, release with a note against the lot, hold pending analysis, or reject. All four are defensible; an undocumented shrug is not [14].

What the vial's appearance can and cannot tell you

Cake appearance is a genuine observable and a strictly limited one. A collapsed, shrunken or melted-back cake, or one fused into a glassy film at the base of the vial, indicates the solid was warmed past the point where it held its dried structure — worth photographing. Powder that has migrated to the shoulder of a vial indicates the parcel was shaken, a different complaint.

What appearance cannot do is quantify chemical change. Deamidation, oxidation and low-level aggregation produce no visual signal in a dried solid: a cake can look immaculate having accumulated measurable change, or look untidy while being chemically intact [9][10]. If the answer matters to the work, it comes from an analytical method run on the received lot — chromatographic purity, read for what the figure actually covers, with mass confirmation — not from inspection. Recording "cake appears normal" as the sole basis for releasing a lot after a known excursion is filing an opinion as a result.

Reducing the chance of the next one

  • Ask before ordering what storage condition the documentation states and what evidence sits behind it. A storage statement with no stability basis is a preference dressed as a specification [2].
  • Ask whether shipments travel in a qualified shipping system with a documented profile and duration claim, or in an insulated box with coolant and good intentions [7].
  • Request an in-parcel logger on high-value lots, specifying a calibrated device with a stated sampling interval so what arrives is usable evidence [8].
  • Time the dispatch. A parcel handed over the day before a long weekend, or delivered to an address nobody attends until evening, buys dwell time nobody planned.
  • Crossing into the United States or Canada, expect the customs hold to dominate the timeline and treat complete brokerage paperwork as a temperature control measure — Health Canada frames these conditions as a continuous obligation across the supply chain, not one that pauses at a border [14].
  • Keep a running excursion log. One warm parcel is an event; four in a year on the same lane is a system out of control, and a defensible reason to change carrier or supplier [5].

None of this produces a certificate. It produces a documented, reasoned position on a specific lot — the most a receiving laboratory can honestly generate without analysing the material — and a growing record of which lanes and suppliers keep delivering warm parcels. The compounds discussed here are supplied for research use only. They are not medicinal products, they are not intended for administration to humans or animals, and nothing above should be read as guidance for anything other than receiving, documenting and storing laboratory material under the conditions its documentation describes.

This product is supplied strictly for qualified laboratory research use only. It is not intended for human or animal consumption, medical use, cosmetic use, nutritional use or recreational use.

References

  1. General Chapter <659> Packaging and Storage RequirementsUnited States Pharmacopeia–National Formulary (USP–NF)
  2. General Chapter <1079> Risks and Mitigation Strategies for the Storage and Transportation of Finished Drug ProductsUnited States Pharmacopeia–National Formulary (USP–NF)
  3. Q1A(R2) Stability Testing of New Drug Substances and ProductsInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2003
  4. Worldwide virtual temperatures for product stability testingJournal of Pharmaceutical Sciences, 1971
  5. General Chapter <1079.2> Mean Kinetic Temperature in the Evaluation of Temperature Excursions During Storage and Transportation of Drug ProductsUnited States Pharmacopeia–National Formulary (USP–NF)
  6. PQS performance specification WHO/PQS/E006/IN05.4: Vaccine Vial MonitorWorld Health Organization, Performance, Quality and Safety (PQS) prequalification
  7. Technical Report No. 39 (Revised 2021): Guidance for Temperature-Controlled Medicinal Products — Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation EnvironmentParenteral Drug Association (PDA), 2021
  8. Annex 9: Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (WHO Technical Report Series, No. 961)World Health Organization Expert Committee on Specifications for Pharmaceutical Preparations, 2011
  9. Solid-state chemical stability of proteins and peptidesJournal of Pharmaceutical Sciences, 1999
  10. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticalsJournal of Pharmaceutical Sciences, 2007
  11. Stability of protein pharmaceuticals: an updatePharmaceutical Research, 2010
  12. Molecular clocksProceedings of the National Academy of Sciences of the United States of America, 2001
  13. The controlled temperature chain (CTC): frequently asked questionsWorld Health Organization, 2023
  14. Guidelines for Temperature Control of Drug Products during Storage and Transportation (GUI-0069)Health Canada, Health Products and Food Branch Inspectorate, 2011